Summary
For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML.
Similar content being viewed by others
References
Bolin RW, Robinson WA, Sutherland J, Hamman RF (1982) Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 50: 1683–1687
Cunningham I, Gee T, Dowling M, et al. (1979) Results of treatment of Ph 1+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 53: 375–395
Goldman JM, Apperley JF, Jones L, et al. (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314: 202–206
Griffin JD (1986) Management of chronic myelogenous leukemia. Semin Hematol 13: Suppl. 1; 20–26
Haut A, Abbott WS, Wintrobe MM, Cartwright GE (1961) Busulfan in the treatment of chronic myelocytic leukemia: the effect of long term intermittent therapy. Blood 17: 1–19
Hehlmann R (1988) Cytostatic therapy of chronic myelogenous leukemia: Review and perspectives. Recent Results of Cancer Research. Springer Verlag, Berlin Heidelberg New York, in press
Kantarjian HM, Keating MJ, Walters RS, et al. (1986) Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 58: 2023–2030
Kantarjian HM, Smith TL, McCredie KB, et al. (1985) Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66: 1326–1335
Kantarjian HM, Velekoop L, McCredie KB, et al. (1985) Intensive combination chemotherapy (RCAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3: 192–200
Kennedy BJ (1972) Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 29: 1052
Koeffler HP, Golde PW (1981) Chronic myelogenous leukemia — new concepts. N Engl J Med 304: 1201–1209, 1269–1274
Niederle N, Kloke O, Doberauer C, Becher R, Beelen DW, Schmidt CG (1986)Alpha-2-Interferon — erste Behandlungsergebnisse bei der chronisch myeloischen Leukämie. Dtsch Med Wochenschr 111: 765–767
Sokal JE, Baccarani M, Tura S, et al. (1985) Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 66: 1352–1357
Sokal JE, Cox EB, Baccarani M, et al. (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63: 789–799
Sharp JC, Joyner MV, Wayne AW, Kemp J, Crofts M, Birch ADJ, Mc Arthur G, Lai S, Sterdale H, Williams Y (1979) Karyotypic conversion in Ph-1-positive chronic myeloid leukemia with combination chemotherapy. Lancet I 1370–1372
Talpaz M, Kantarjian HM, Mc Credie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferonalpha in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069
Thomas ED, Clift RA, Fefer A, et al. (1986) Marrow transplantation for the treatment of chronic mylogenous leukemia. Ann Intern Med 104: 155–163
Silver RT, Mick R, Cooper R, et al. (1987) Comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B. Cancer 60: 1442–1448
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hehlmann, R., Anger, B., Messerer, D. et al. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut 56, 87–91 (1988). https://doi.org/10.1007/BF00633471
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00633471